fbpx
QQQ
-0.67
342.93
-0.19%
DIA
-1.12
344.53
-0.33%
SPY
-1.15
425.63
-0.27%
TLT
+ 0.45
140.61
+ 0.32%
GLD
+ 0.01
174.04
+ 0.01%

Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week

April 27, 2021 10:29 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week

Cannabis Countdown: Top 10 Marijuana and Psychedelics Industry News Stories of the Week

Welcome to the Cannabis Countdown, the Legal Marijuana Industry’s Number One Curated Weekly News Recap.

In This Week’s Edition, We Recap and Countdown the Top 10 Cannabis and Psychedelics Industry News Stories for the Week of April 19th – 25th, 2021.

Without further ado, let’s get started.

Yahoo Finance readers, please click here to view the full article.

10. California Bill to Decriminalize Psychedelics Moves Forward: Legislation’s Sponsor Talks ‘Learning Curve,’ Why MDMA, LSD Are Included

A Bill to Decriminalize Psychedelic Substances in California is Quickly Moving up the Legislative Ladder

Introduced in February by Sen. Scott Wiener, SB 519 would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychoactive drugs including Psilocybin, psilocyn, DMTIbogaineMescalineLSDKetamine and MDMA. The legislation would also expunge the criminal records of those charged with low-level Psychedelics convictions.

READ FULL CALIFORNIA PSYCHEDELICS ARTICLE

9. New House Bills Would Make Cannabis Businesses Eligible for Federal Small-Business Aid

Lawmakers in the U.S. House of Representatives Have Introduced Three New Bills to Make State-Legal Marijuana Businesses Eligible for Federal Small Business Services, Including Loans, Disaster Relief and Grant Programs

The package of legislation is aimed at establishing parity for cannabis businesses, which are currently prohibited from receiving federal aid due to marijuana still being classified as a Schedule I controlled substance. The country’s legal cannabis industry nevertheless now supports nearly 320,000 full-time jobs in the U.S., according to industry estimates.

READ FULL CANNABIS BUSINESS AID ARTICLE

8. Researchers Slam Drug War at Federally Hosted Psychedelics Event

A Federal Health Agency Kicked Off a Speaker Series on Thursday That’s Dedicated to Recapping Science on the Therapeutic Potential of Psilocybin Mushrooms

And the experts who spoke at the first event said in response to Marijuana Moment’s questions that federal drug laws are out of step with voters and undermine the research objectives of the scientific community. The National Cancer Institute (NCI), under the National Institutes of Health (NIH), which is hosting the events, says that while federal law classifies the psychedelic as a Schedule I substance with no currently accepted medical value, clinical trials “are researching psilocybin to treat cancer-related depression, for example, and moreover for its potential medicinal application in treating a range of severe psychiatric disorders.”

READ FULL PSYCHEDELICS EVENT ARTICLE

7. Supreme Acquisition Has Canada’s Largest Cannabis LP Poised to Grow Even Bigger

Canopy Growth, Canada’s Largest Cannabis Licensed Producer Appears Set to for Another Major Growth Spurt Following the Company’s Suprise Announcement That it Would Be Acquiring Rival LP Supreme Cannabis

Canopy Growth (TSX:WEED) (NYSE:CGC) (FRA: 11L1) announced recently that it would be acquiring Supreme Cannabis (TSX:FIRE) (OTCQX:SPRWF) (FRA: 53S1)  for a cool $435 million. It’s a somewhat curious move, as Canopy Growth has been divesting, not acquiring, Canadian assets recently. Reaction from investors has been muted, as the stock price has not seen a large swing in either direction since the deal was announced.

READ FULL CANOPY SUPREME ARTICLE

6. Psychedelics: A Growing Market in Canada

For Centuries, Psychedelics Have Provided Spiritual and Medicinal Benefits for Various Cultures

As the world deals with a global mental health crisis, Canada has become a home for research into the therapeutic potential of psychedelics in drugs. As research continues, so does the push for psychedelic solutions to mental health problems. Whether they are natural or synthetic, psychedelics are psychoactive substances that can affect a user’s perception, mood, and cognitive processing. Two of the most widely studied substances in Canada are psilocybin and Ketamine.

READ FULL CANADA PSYCHEDELICS ARTICLE

5. Marijuana Firms Could Face Higher Taxes Via Biden Spending Plan and State Rules

Cannabis Businesses Have Paid Higher Taxes Than Mainstream Companies for Years Thanks to Section 280E of the Internal Revenue Code

Now cannabis operators – especially retailers – might face an even bigger tax bill from Uncle Sam as well as some states. Two noteworthy developments could boost marijuana firm taxes:

  • President Joe Biden’s $2 billion infrastructure plan proposes raising the federal corporate tax rate from 21% to 28%.
  • States legalizing recreational marijuana programs increasingly are limiting vertical integration to small operators, or microbusinesses. By contrast, stand-alone marijuana retailers face a higher federal tax burden than vertical operations given the limited number of deductions retailers can take, tax experts say.

The prospect of such a one-two punch has raised alarm bells among cannabis tax experts.

READ FULL BIDEN CANNABIS

4. Worthy or Superfluous? Psychedelics Experts Discuss the Sector’s Ongoing Patent Debate

The Race is Continually Heating Up in the Psychedelics Space

An array of companies, educational institutions and investors have already obtained patents on formulations, processes, compounds and other aspects of psychedelics treatment. The race has heated to such a degree that certain compounds, like psilocybin, have patent trackers to keep abreast of the market. While exciting, the development of the space creates a discussion around psychedelic patent ethics. In early 2021, Compass Pathways (NASDAQ:CMPS) made headlines for its patent applications.

READ FULL PSYCHEDELIC PATENTS ARTICLE

3. Cannabis Analyst: SAFE Act Won’t Make it to Senate Vote, But It’s Part of a ‘Compromise Scenario’ on Federal Legalization

The U.S. House of Representatives Voted for the Secure and Fair Enforcement Banking Act for the Fourth time, but the Bill Aimed at Enabling Banks to Provide its Services to State-Legal Cannabis Businesses Never Before Passed to the Senate Floor

Cantor Fitzgerald’s analyst Pablo Zuanic doesn’t see the bill reaching a Senate vote either, as leading Democrats there are pushing for broader reform, and not for “isolated federal level changes” for the industry. Back in March, Senate Majority Leader Chuck Schumer held a short conference with Senate Finance Committee Chairman Ron Wyden (D-OR) and Sen. Cory Booker (D-NJ) sharing their actions on drafting extensive reform legislation. Just last week, Schumer announced his plans to introduce a federal legalization bill soon. “Once it is introduced, it will go on the floor,” Schumer said.

READ FULL SAFE ACT ARTICLE

2. MindMed Becomes the U.S.’ Second Public Psychedelics Company

They’re Nearer Than Ever, But Don’t Compare it to Cannabis

Psychedelic drug developer MindMed (NEO: MMED) (OTCQB:MMEDF) (FRA: MMQ) will be listed on the NASDAQ today, becoming the second company of its kind to go public in the US. Compass Pathways (NASDAQ:CMPS) is already trading publicly, and Peter Thiel-backed ATAI Life Sciences could make it three: It just filed for an IPO last week. According to MindMed CEO JR Rahn, the growth of psychedelics companies is tied to increased awareness of mental health challenges during the pandemic. MindMed’s therapeutics try to improve mental health with treatments that utilize ingredients including MDMALSD, and Psilocybin of shrooms fame.

READ FULL MINDMED ARTICLE

1. These States Could Still Legalize Recreational or Medical Cannabis in 2021

Several More States Could Legalize Adult-Use or Medical Marijuana Before Their Legislative Sessions Adjourn in 2021, Possibly Generating Hundreds of Millions of Dollars in New Business Opportunities in the Coming Years

Now that New Jersey and New York legalized recreational marijuana programs – which together are expected to produce more than $4 billion in annual sales within a few years of launching – industry experts are keeping a close eye on the East Coast states of ConnecticutDelaware and Rhode IslandVirginia and New Mexico already legalized adult-use through their legislatures this year. Together these two states are expected to generate around $2 billion in annual revenue five years after sales begin.

READ FULL 2021 CANNABIS LEGALIZATION

Image Sourced from Pixabay

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.


Related Articles

Canopy Growth Exec: CBD Beverage Market Will Hit $1.5B In Coming Years

Tara Rozalowsky, vice president of beverages and edibles at Canopy Growth Corp (NASDAQ: CGC), discussed the latest developments on the CBD front at the Benzinga Cannabis Capital Conference on Thursday. read more

The Week In Cannabis: Earnings, Financings, M&A, Cookies U, DEA, DJ Khaled, And More

In an earnings-heavy week, cannabis stocks experienced considerable volatility. read more

Canopy Growth Names Martha Stewart As Its Official Strategic Advisor

Canadian cannabis giant Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) will deepen its collaboration with household guru Martha Stewart, who has agreed to serve as the company's official strategic advisor. Stewart's CBD Saga read more

Boston Beer Company To Develop Non-Alcoholic Cannabis Beverages

The Boston Beer Company Inc (NYSE: SAM) is creating a Canadian-based subsidiary focusing on research and development of non-alcoholic  cannabis beverages. read more